PF-3882845, also referred to as PF-03882845 or PF 03882845, is a selective non-steroidal mineralocorticoid receptor antagonist commonly employed in pharmacological and translational studies. Developed within PF-3882845 Pfizer research programs, the compound is investigated for its effects on aldosterone-mediated signaling mechanisms. Registered under CAS 1023650-66-9, it is particularly relevant to research focused on cardiovascular and renal disorders where high receptor selectivity is required.
Scientists frequently evaluate PF-3882845 chemical structure to better characterize its receptor binding behavior and selectivity characteristics. In addition, PF-3882845 molecular weight is an important parameter during assay preparation and compound validation, supporting accurate dosing and reproducibility across experimental systems.
Application of PF-3882845
Application PF-3882845 is primarily focused on studies involving mineralocorticoid receptor signaling and associated disease mechanisms. The compound is used in both early-stage discovery and advanced preclinical models where precise receptor targeting is required.
- evaluation of mineralocorticoid receptor inhibition in renal and cardiovascular models
- comparative studies with steroidal antagonists to assess selectivity and potency
- screening workflows for pathway-specific compound validation
Its well-characterized profile makes PF-03882845 a reliable reference compound in studies investigating fibrosis, inflammation, and electrolyte regulation pathways.
In Vivo
In vivo, PF-03882845 has been evaluated in preclinical and early clinical settings, demonstrating activity in models of aldosterone-mediated kidney damage. Studies indicate its ability to reduce biomarkers associated with renal stress, supporting its use in translational research. These findings highlight its relevance in dose-response analysis and therapeutic pathway exploration.
Biochemical and Physiological Actions
The primary mechanism of PF-3882845 involves selective antagonism of the mineralocorticoid receptor, which regulates fluid balance, blood pressure, and tissue remodeling processes. Unlike steroidal compounds, PF-3882845 shows improved selectivity, minimizing off-target interactions with other nuclear receptors.
This specificity allows researchers to isolate MR-driven biological responses, making PF 03882845 valuable for studies focused on receptor signaling, gene expression changes, and downstream physiological effects.
Features and benefits of PF-3882845
PF-3882845 offers a combination of well-documented activity, selectivity, and experimental relevance, making it suitable for a wide range of research applications. When sourced as EBC-421063, it is supported by quality control standards and analytical validation.
- high selectivity toward mineralocorticoid receptor targets
- consistent quality with validated analytical data
- relevance for both in vitro and in vivo research models
As part of a broader catalog of bioactive molecules, PF-3882845 supports efficient compound selection and integration into research workflows, enabling scientists to advance studies with confidence and precision.
Powered by Bioz